Central airway stenting in oncology

Cover Page

Cite item

Full Text

Abstract

Introduction. Malignant central airway obstruction and malignant tracheoesophageal fistula in the context of tumor development are potentially life-threatening conditions which usually require immediate intervention. Airway stenting is one of the safest and most effective methods of airway patency restoration in patients with malignant obstruction of the central airways and restoration of continuity in patients with malignant tracheoesophageal fistula.

Aim. To evaluate the significance of self-expandable metal stents in palliative treatment of patients with malignant central airway obstruction and malignant tracheoesophageal fistula.

Materials and methods. Between 2017 and 2021 at the N. N. Blokhin National Medical Research Center of Oncology, 55 patients were observed and treated and underwent trachea stenting per the results of bronchoscopy in combination with esophagogastroduodenoscopy. The 1st group included 25 patients with malignant tracheoesophageal fistulas, the 2nd group included 30 patients with malignant central airway obstruction.

Results. In the 1st group, stenting was successful in 25 (100 %) cases which allowed to adequately seal the fistula. Stent migration was observed in 1 (4 %) patient with tracheoesophageal fistula in the context of stenosing cancer of the thoracic esophagus. In the 2nd group, stenting was successful in 30 (100 %) cases. Stent migration was not observed in this patient group. In both groups, there were no complications after stent implantation. Installation of tracheal stent allowed to improve patients’ quality of life and provide a possibility for successful special treatment through low-trauma manipulation.

Conclusion. According to the obtained data, endoscopic trachea stenting is the most important method of palliative treatment of tumor-related trachea lesions with development of tracheoesophageal fistulas, malignant central airway obstructions and associated sub- and decompensated pulmonary insufficiency.

About the authors

M. A. Krylovetskaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: mariyakrilo@gmail.com
ORCID iD: 0000-0002-0868-3948

Maria Aleksandrovna Krylovetskaia

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

M. V. Makarova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-5277-7757

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

I. G. Komarov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-3495-5521

24 Kashirskoe Shosse, Moscow 115522

Bld. 1, 2 / 1 Barricadnaya St., Moscow 125993

Russian Federation

O. A. Malikhova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-0829-7809

24 Kashirskoe Shosse, Moscow 115522

Bld. 1, 2 / 1 Barricadnaya St., Moscow 125993

Russian Federation

L. V. Cherkes

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-6943-6457

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.